- Home
- CRSP vs CWEN Comparison
CRSP vs CWEN Comparison
Compare CRSP & CWEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRSP
- CWEN
- Stock Information
- Founded
- CRSP 2013
- CWEN 2012
- Country
- CRSP Switzerland
- CWEN United States
- Employees
- CRSP N/A
- CWEN N/A
- Industry
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- CWEN Electric Utilities: Central
- Sector
- CRSP Health Care
- CWEN Utilities
- Exchange
- CRSP Nasdaq
- CWEN Nasdaq
- Market Cap
- CRSP 3.4B
- CWEN 3.1B
- IPO Year
- CRSP 2016
- CWEN 2013
- Fundamental
- Price
- CRSP $47.87
- CWEN $27.44
- Analyst Decision
- CRSP Buy
- CWEN Buy
- Analyst Count
- CRSP 21
- CWEN 7
- Target Price
- CRSP $75.42
- CWEN $30.86
- AVG Volume (30 Days)
- CRSP 2.7M
- CWEN 723.8K
- Earning Date
- CRSP 02-11-2025
- CWEN 02-24-2025
- Dividend Yield
- CRSP N/A
- CWEN 6.13%
- EPS Growth
- CRSP N/A
- CWEN 124.49
- EPS
- CRSP N/A
- CWEN 1.04
- Revenue
- CRSP $37,314,000.00
- CWEN $1,364,000,000.00
- Revenue This Year
- CRSP $227.76
- CWEN $9.44
- Revenue Next Year
- CRSP $353.05
- CWEN $7.23
- P/E Ratio
- CRSP N/A
- CWEN $26.47
- Revenue Growth
- CRSP N/A
- CWEN 2.33
- 52 Week Low
- CRSP $36.52
- CWEN $20.63
- 52 Week High
- CRSP $90.62
- CWEN $30.92
- Technical
- Relative Strength Index (RSI)
- CRSP 58.27
- CWEN 66.91
- Support Level
- CRSP $38.28
- CWEN $25.89
- Resistance Level
- CRSP $55.88
- CWEN $26.64
- Average True Range (ATR)
- CRSP 2.87
- CWEN 0.59
- MACD
- CRSP 1.07
- CWEN 0.17
- Stochastic Oscillator
- CRSP 54.50
- CWEN 95.74
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
About CWEN Clearway Energy Inc. Class C
Clearway Energy Inc is a publicly-traded energy infrastructure investor with a focus on investments in clean energy and owner of modern, sustainable and long-term contracted assets across North America. The company segments its operations into conventional power generation, renewables and thermal divisions.